South San Francisco, CA, United States of America

Karl Yen

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Genentech, Inc.. Active years: 2022-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Karl Yen

Introduction

Karl Yen is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of medicine, particularly in the treatment of atopic dermatitis. With a total of 2 patents, his work has garnered attention in the scientific community.

Latest Patents

One of Karl Yen's latest patents is titled "Uses of IL-13 Antagonists for Treating Atopic Dermatitis." This patent outlines methods for treating atopic dermatitis and reducing its severity through the administration of IL-13 antagonists. His innovative approach provides new avenues for patients suffering from this condition.

Career Highlights

Throughout his career, Karl has worked with prominent companies such as Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these leading organizations has allowed him to develop and refine his inventions, contributing to advancements in medical treatments.

Collaborations

Karl has collaborated with notable colleagues, including Theodore A. Omachi and Kendra Debusk. These partnerships have played a crucial role in the development of his innovative ideas and patents.

Conclusion

Karl Yen's contributions to the field of medicine through his patents and collaborations highlight his dedication to improving treatment options for patients. His work continues to inspire advancements in medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…